How has the biosimilar therapeutic peptides market evolved, and where is it heading next?
The biosimilar therapeutic peptides market size has grown exponentially in recent years. It will grow from $2.06 billion in 2024 to $2.68 billion in 2025 at a compound annual growth rate (CAGR) of 30.3%. The growth in the historic period can be attributed to increasing demand for cost-effective therapeutics, regulatory support and frameworks, patent expirations of biologic drugs, rising incidence of chronic diseases, and established manufacturing processes.
The biosimilar therapeutic peptides market size is expected to see rapid growth in the next few years. It will grow to $4.87 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to expanding therapeutic applications, the global aging population, market competitiveness, strategic collaborations and partnerships, and patient preference for non-invasive therapies. Major trends in the forecast period include advancements in biotechnology, increasing demand for biologics, technological innovations in manufacturing, focus on cost-efficiency and access to healthcare, and technological advancements.
Get Your Free Sample of The Global Biosimilar Therapeutic Peptides Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3423&type=smp
What are the key drivers behind the rapid expansion of the biosimilar therapeutic peptides market?
The increasing aging population is projected to surge the number of patients with chronic diseases, contributing to the biosimilar therapeutic peptides market’s growth. Elderly people are more prone to various chronic diseases, which are surging the old age population rapidly across the world and is predicted to continue over the forecast period. According to the World Health Organization (WHO), the world’s population over the age of 60 is expected to reach 2 billion by the end of 2050. Moreover, according to the World Population Prospects, the number of people aged 80 and above is likely to increase from 143 million in 2019 to 426 million in 2050. Biosimilar therapeutic peptides are used for the treatment of various chronic diseases and cancers. The expected increase in the ageing population suffering from various chronic conditions will drive the growth of biosimilar therapeutic peptide market.
What is the segmentation for the biosimilar therapeutic peptides market?
The biosimilar therapeutic peptides market covered in this report is segmented –
1) By Type: Innovative, Generic
2) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations
3) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders
Subsegments:
1) By Innovative: Long-Acting Peptides, Combination Peptides
2) By Generic: Monoclonal Antibodies, Hormones, Enzymes
Order your report now for swift delivery
Who are the most influential companies in the biosimilar therapeutic peptides market?
Major companies operating in the biosimilar therapeutic peptides market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceuticals Co. Ltd., Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, BioXpress Therapeutics SA, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Lonza Inc., Stada Arzneimittel AG, Ipsen S.A, Biocon Biopharmaceuticals Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Alvogen Pharma US Inc., Corden Pharma GmbH, Bachem Holding AG, PolyPeptide Laboratories Ltd., PeptiDream Inc., Coherus BioSciences Inc., Celltrion Inc., BioPartners Inc., Samsung Bioepis Co. Ltd.
What are the most influential trends expected to drive the biosimilar therapeutic peptides market forward?
Major companies in the biosimilar therapeutic peptide market are developing a research platform for optimizing peptide synthesis, enhancing production efficiency, and ensuring consistent quality, from discovery to commercialization. Biodrug Design Accelerator, a platform to manage research processes for peptide drug discovery, which many regard as a promising frontier in the field of new drug development. For instance, in May 2023, Fujitsu Limited, a US-based toy manufacturing and entertainment company, launched the Biodrug Design Accelerator platform to accelerate peptide drug discovery research. Biodrug Design Accelerator will support peptide drug discovery scientists in pharmaceutical companies to accelerate and improve the efficiency of peptide drug development, specifically through the cycles design, make, test, analyze (DMTA), ultimately enabling accelerated and informed design of peptide drug candidates as well as efficient communication among scientists regarding synthesis and testing.
Which geographic trends are shaping the biosimilar therapeutic peptides market, and which region has the highest market share?
North America was the largest region in the biosimilar therapeutics peptides market in 2024. Middle East is expected to be the fastest growing region in the biosimilar therapeutic peptides market report during the forecast period. The regions covered in the biosimilar therapeutic peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Biosimilar Therapeutic Peptides Market Report 2025 Offer?
The biosimilar therapeutic peptides market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Biosimilar therapeutic peptides refer to a peptide drug that is used in place of or in addition to peptide hormones when endogenous levels tend to decline. Therapeutic peptides that are biosimilar have applications in the treatment of cancer, metabolic, pulmonary, cardiovascular, and other illnesses.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3423
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
